Benefits of Temporary Intrathecal Baclofen Therapy: Management of Tone and Spasticity
Melissa Ann Eppinger*, Thomas J. Sernas and Catherine Anne Mazzola
Goryeb Children's Hospital at Morristown Medical Center, USA
*Corresponding author: Melissa Ann Eppinger, Goryeb Children's Hospital, 100 Madison Ave. Morristown, NJ 07960, Tel: 973-326-9000, Fax: 973-326-9001, E-mail: email@example.com
Int J Brain Disord Treat, IJBDT-1-003, (Volume 1, Issue 1), Case Series; ISSN: 2469-5866
Received: August 03, 2015 | Accepted: September 07, 2015 | Published: September 09, 2015
Citation: Eppinger MA, Sernas TJ, Mazzola CA (2015) Benefits of Temporary Intrathecal Baclofen Therapy: Management of Tone and Spasticity. Int J Brain Disord Treat 1:003. 10.23937/2469-5866/1510003
Copyright: © 2015 Eppinger MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: Our objectives are to report the efficacy and safety of intrathecal baclofen (ITB) therapy for the temporary treatment of spasticity and dystonia, and to illustrate the benefit of temporary ITB therapy while patients are in rehabilitation.
Method: This is a retrospective case series of three patients with spasticity and dystonia who were treated with ITB. All patients had their pump and catheter explanted after their movement disorder resolved and their abilities improved, and they were slowly weaned off intrathecal baclofen (ITB).
Results: ITB therapy prevented the development of complications related to inadequately treated spasticity and dystonia. All patients improved clinically to the extent where the ITB could be tapered off and discontinued. Each patient had their pump and catheter hardware explanted successfully.
Conclusion: ITB therapy is effective in decreasing complications associated with hypertonicity and spastic dystonia. Removal of hardware is feasible for patients with clinical improvement after careful, decreasing titration of baclofen thereby avoiding withdrawal symptoms.
Dystonia, Intrathecal Baclofen Therapy, ITB, Spasticity, Spastic Dystonia
Intrathecal baclofen (ITB), Ashworth Scale (AS), Central Nervous System (CNS), Gamma aminobutyric acid (GABAB), Spinal Cord Injury (SCI)
Spasticity and dystonia may develop as a consequence of brain or spinal cord injury (SCI) [1-8]. Central nervous system (CNS) injury may be permanent or temporary, depending on the etiology of brain or spinal cord injury. In anoxic brain injury, there may be transient or reactive demyelination due to cell death or cell dysfunction. If there is ischemia without true infarction, or cell death, there may be some ability of the brain to repair itself or reconstitute the myelination of axons within the white matter of the brain. There also may be some degree of plasticity of the brain to reassign functional capacities that may be retained into young adulthood.
Baclofen is a muscle relaxant medication used for the treatment of patients diagnosed with spasticity and dystonia . This gamma aminobutyric acid B (GABAB) receptor agonist acts in the dorsal horn of the spinal cord and causes an inhibitory influence on the alpha motor neurons [2,10-15]. The increased inhibition between the CNS and the muscles ultimately leads to the reduction of spasticity and dystonia [5,13,16]. Baclofen also acts by reversing brainstem reflex excitability observed in patients with SCI [11,13,15,17]. Oral baclofen absorbed through the intestinal lining and then into the blood, must cross the blood brain barrier and has limited efficacy because of poor penetration . When patients have medically intractable spasticity or dystonia, then ITB should be considered [2,6,15,16,18].
We present a small case series of three patients treated with ITB who all improved to such an extent, that they wanted their ITB hardware explanted. Temporary ITB provided temporary and timely reduction in tone and dystonia, so that their rehabilitation was optimized.
A 17-year old healthy male suffered an anoxic brain injury after a drug overdose. He developed dystonic posturing, spastic quadriparesis and contractures despite physical therapy, oral baclofen (120 mg daily) and botulinum toxin injections performed by his physiatrist. He developed dislocation and subluxation of his right shoulder. 18 months after his injury, his spasticity was a 3/5 in his upper extremities and 4/5 in his lower extremities as per the Ashworth Scale (AS). After a successful test dose, the patient underwent implantation of an ITB pump with a spinal catheter. Physical therapy was restarted as an inpatient and the patient was transferred to acute, inpatient rehabilitation. The patient's spastic paraparesis improved to a 2/5 on the AS score. He continued to make functional improvements, including attending college classes, and he was ambulating with a walker. Four years post-pump implantation, the patient requested the pump to be removed. His daily ITB dose had been slowly titrated down to 24 μg daily over several months. The patient did well after surgery and has maintained his independent, ambulatory neurological status.
A 41-year old woman suffered an intracerebral hemorrhage and vasospasm. She developed post-hemorrhagic hydrocephalus, in addition to severe spastic dystonia and quadriparesis measured to be 4/5 as per the AS score. Approximately 24 months after the initial event, she underwent a test dosage and ITB was initiated. The patient tolerated the surgical implantation well and was transferred to acute, in-patient rehabilitation. A marked improvement in the patient's spasticity was noted to be 1 to 2/5 throughout at 191 μg of ITB daily. Post-ITB, the patient made significant functional improvements. Her ability to walk long distances with a walker increased. At four years post-ITB initiation, no residual spasticity was documented, a 1/5 according to the AS score. Five years after the pump was placed, the patient was weaned off of intrathecal baclofen (ITB) and the pump was removed. The patient continued to make significant progress and is able to walk without a walker.
A 13-year old boy suffered a traumatic commotio cordis after a baseball line-drive to the chest, and anoxic brain damage. This lead to severe spastic quadriparesis and spastic dystonia. The patient went to inpatient rehabilitation and was then discharged with aggressive outpatient therapies, and oral valium and baclofen. His physiatrist referred him for ITB after five months of uncontrollable spasticity, spastic dystonia and developing contractures. His spasticity was a 3/5 in his upper extremities and 4/5 in his lower extremities as per the AS score. ITB therapy was initiated after a successful test dose. Post-operatively, the child was sent back for more acute, in-patient rehabilitation. Three years after ITB initiation, the ambulatory patient and his family requested to have the pump removed. The patient's spastic quadriparesis significantly improved over that time span to 1/5 as per the AS in all extremities. The patient was weaned off of ITB and the pump and catheter were explanted without complication. The patient continued to improve.
Spasticity and dystonia are frequent complications of brain or spine injury. Most patients are treated with physical therapy and oral medications without adequate control of symptomatology. However, for patients with medically intractable spasticity and dystonia, ITB therapy can be used for short or long term duration. It is best to start therapy before severe contractures develop.
All of our patients had a significant reduction of their spasticity and dystonia, and gained more independent mobility. They made significant functional gains. Reduction of dystonia and dysarthria were also noted by patients and their families. Three to five years following ITB, all patients no longer required ITB therapy, and had their hardware explanted without complication. Patients were followed annually for three years, by the senior neurosurgeon and more often by their physiatrist, after hardware explantation. The three patients have no spasticity, dystonia or long term complications after explantation.
The efficacious use of ITB therapy following brain or spine injury is well documented. In a study of 18 pediatric and adult patients with spasticity of supraspinal origin, continuous ITB was recommended following a traumatic or hypoxic brain event . The article reports that patients were initially given oral antispasmodic medication without relief. However, due to multiple parts of the patients' bodies being affected by spasticity, other less invasive treatments such alcohol blocks and botulinum toxin injections were not administered . A reduction of patient's spasticity decreased according to the AS score from 4.5/5 to 2.33/5 . Therefore, it could be inferred that a significant improvement in the patients', as well as their caretakers' quality of life was made following ITB pump placement .
There is also scientific literature regarding recommended treatments for spasticity and dystonia after stroke [19-21]. Wissel et al. reports that approximately 25% of stroke patients experienced increased muscle tone not long after their anoxic event . Patients that developed post-stroke spasticity tended to have more pain, and a reduced quality and ease of life [20,21]. Dietz et al. discusses that physicians often feel constricted with the treatment options available for these patients with muscle disorders . Too often their spasticity becomes worse over time, resulting in decreased dexterity, and an increased dependence and burden for their caretakers [23,24]. Currently, a majority of the management for post-stroke patients with spasticity are based off of cerebral palsy and multiple sclerosis studies [20,24]. Dietz et al. suggests that treatment of these patients should be concentrated on re-gaining the patient's independence, in addition to preventing the development of complications . Anti-spastic drug therapy such as ITB therapy has the potential to decrease muscle tone, and consequently improve the care for these patients [21,23].
Removal of the ITB pump and catheter after improvement of spasticity and dystonia is feasible and safe. Clinicians must carefully taper the patient off of the ITB slowly prior to the surgical explantation. Each patient underwent a weaning schedule that was as prescribed by the physiatrist and involved a 15% decrease every month until the intrathecal dose was less than 75 μg per day. The pumps were set at a "minimum infusion rate" for one month before surgical hardware explanation was scheduled to prevent damage of the device caused by the pump rotor . Unlike in true ITB withdrawal, none of our patients experienced acute withdrawal symptoms because, of the slowly decreasing titration [5,9]. Many publications report the effectiveness of ITB for reducing tone, spasticity and dystonia associated with brain or spine injury [1-4,7,14]. However, we found only one report of baclofen pump explantation in patients after improved spasticity . The management of patients with spasticity can improve if ITB therapy is implemented as a therapeutic intervention earlier rather than after an inadequate response to other treatment modalities are noted.
1. Early ITB is recommended for patients with medically intractable spasticity and dystonia.
2. Select patients with clinical improvement of their symptomatology may be safely weaned off ITB with slow tapering, if ITB is no longer necessary.
3. Pumps and catheters can be safely explanted.
Declaration of Interest
The authors report no declarations of interest.
Becker R, Alberti O, Bauer BL (1997) Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 244: 160-166.
Berman CM, Eppinger MA, Mazzola CA (2015) Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity. Childs Nerv Syst 31: 405-413.
Dénes Z, Klauber A, Both B, Lóránd E (2012) [Results of intrathecal baclofen therapy on spasticity in patients with brain injury]. Ideggyogy Sz 65: 243-248.
Francisco GE, Hu MM, Boake C, Ivanhoe CB (2005) Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj 19: 359-364.
Mohammed I, Hussain A (2004) Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol 4: 6.
Morton RE, Gray N, Vloeberghs M (2011) Controlled study of the effects of continuous intrathecal baclofen infusion in non-ambulant children with cerebral palsy. Dev Med Child Neurol 53: 736-741.
Sindou M, Georgoulis G, Mertens P (2014) Intrathecal baclofen therapy. In: Lyons, France, Neurosurgery for spasticity: a practical guide for treating children and adults. Springer-Verlag Wien, 69-97.
Taira T (2009) Intrathecal administration of GABA agonists in the vegetative state. Prog Brain Res 177: 317-328.
Smith TR, Mithal DS, Park A, Bohnen A, Adel J, et al. (2013) Emergent intrathecal baclofen withdrawal after pseudomeningocele aspiration. Pain Physician 16: E113-118.
Cameron MH (2013) Tone abnormalities. In: St. Louis, MO, Physical agents in rehabilitation: from research to practice. (4th edn), Elsevier Saunders, 83-91.
Dykstra D, Stuckey M, DesLauriers L, Chappuis D, Krach L (2007) Intrathecal baclofen in the treatment of spasticity. In: Sakas DE, Simpson B, Krames ES, Operative neuromodulation: volume 1: functional neuroprosthetic surgery. an introduction. Springer-Verlag Wien, Austria, 163-171.
Greenberg MS (2006) Functional Neurosurgery: Spasticity. In: Handbook of Neurosurgery. (6th edn), Thieme Medical Publishers, New York, 367-370.
Kumru H, Kofler M (2012) Effect of spinal cord injury and of intrathecal baclofen on brainstem reflexes. Clin Neurophysiol 123: 45-53.
Posteraro F, Calandriello B, Galli R, Logi F, Iardella L, et al. (2013) Timing of intrathecal baclofen therapy in persons with acquired brain injury: influence on outcome. Brain Inj 27: 1671-1675.
Uchiyama T, Nakanishi K, Fukawa N, Yoshioka H, Murakami S, et al. (2012) Neuromodulation using intrathecal baclofen therapy for spasticity and dystonia. Neurol Med Chir (Tokyo) 52: 463-469.
Kroin JS, Bianchi GD, Penn RD (1993) Intrathecal baclofen down-regulates GABAB receptors in the rat substantia gelatinosa. J Neurosurg 79: 544-549.
Kumru H, Kofler M, Valls-Solé J, Portell E, Vidal J (2009) Brainstem reflexes are enhanced following severe spinal cord injury and reduced by continuous intrathecal baclofen. Neurorehabil Neural Repair 23: 921-927.
Schiess MC, Oh IJ, Stimming EF, Lucke J, Acosta F, et al. (2011) Prospective 12-month study of intrathecal baclofen therapy for poststroke spastic upper and lower extremity motor control and functional improvement. Neuromodulation 14: 38-45.
Demetrios M, Khan F, Turner-Stokes L, Brand C, McSweeney S (2013) Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev 6.
Harrison RA, Field TS (2015) Post stroke pain: identification, assessment, and therapy. Cerebrovasc Dis 39: 190-201.
Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, et al. (2010) Early development of spasticity following stroke: a prospective, observational trial. J Neurol 257: 1067-1072.
Welmer AK, von Arbin M, Widén Holmqvist L, Sommerfeld DK (2006) Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis 21: 247-253.
Dietz V, Sinkjaer T (2007) Spastic movement disorder: impaired reflex function and altered muscle mechanics. Lancet Neurol 6: 725-733.
Martin A, Abogunrin S, Kurth H2, Dinet J (2014) Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat 10: 111-122.